Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about RayzeBio, Inc. Common Stock
RayzeBio, Inc. Common Stock News
RayzeBio, Inc. Common Stock Quantitative Score
About RayzeBio, Inc. Common Stock
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
RayzeBio, Inc. Common Stock Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
RayzeBio, Inc. Common Stock Financials
Table Compare
Compare RYZB metrics with: | |||
|---|---|---|---|
Earnings & Growth | RYZB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RYZB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RYZB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RYZB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
RayzeBio, Inc. Common Stock Income
RayzeBio, Inc. Common Stock Balance Sheet
RayzeBio, Inc. Common Stock Cash Flow
RayzeBio, Inc. Common Stock Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Sell |
| Return on Assets | Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
RayzeBio, Inc. Common Stock Executives
| Name | Role |
|---|---|
| Mr. Arvind Kush | Chief Financial Officer |
| Dr. Kenneth Song M.D. | President, Chief Executive Officer & Director |
| Dr. Susan Moran M.D. | Chief Medical Officer |
| Dr. Gary G. Li Ph.D. | Senior Vice President of Biology & Translational Medicine |
| Dr. Nicholas D. Smith Ph.D. | Senior Vice President of Chemistry Innovation |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Arvind Kush | Chief Financial Officer | Male | 1983 | 714.76K |
| Dr. Kenneth Song M.D. | President, Chief Executive Officer & Director | 1975 | 646K | |
| Dr. Susan Moran M.D. | Chief Medical Officer | 1969 | 559.84K | |
| Dr. Gary G. Li Ph.D. | Senior Vice President of Biology & Translational Medicine | -- | ||
| Dr. Nicholas D. Smith Ph.D. | Senior Vice President of Chemistry Innovation | -- |
RayzeBio, Inc. Common Stock Insider Trades
| Date | 26 Feb |
| Name | VIKING GLOBAL INVESTORS LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 1743556 |
| Date | 19 Sep |
| Name | Redmile Group, LLC |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | C-Conversion |
| Shares | 864509 |
| Date | 19 Sep |
| Name | Redmile Group, LLC |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | C-Conversion |
| Shares | 494687 |
| Date | 19 Sep |
| Name | Redmile Group, LLC |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | C-Conversion |
| Shares | 498510 |
| Date | 19 Sep |
| Name | Redmile Group, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | C-Conversion |
| Shares | 864509 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 26 Feb | VIKING GLOBAL INVESTORS LP | 10 percent owner | Disposed | J-Other | 1743556 |
| 19 Sep | Redmile Group, LLC | 10 percent owner | Acquired | C-Conversion | 864509 |
| 19 Sep | Redmile Group, LLC | 10 percent owner | Acquired | C-Conversion | 494687 |
| 19 Sep | Redmile Group, LLC | 10 percent owner | Acquired | C-Conversion | 498510 |
| 19 Sep | Redmile Group, LLC | 10 percent owner | Disposed | C-Conversion | 864509 |